Publication date: Feb 14, 2020
PALM BEACH, Florida, Feb. 13, 2020 /PRNewswire/ — Opioid drugs are and have been a God-send for many patients whose severe, excruciating pain had no other drug or device to allow them to escape from its throes. .. But we all know that the other side of that coin has created a social hell of its own.
That is the impetus for the ever increasing non-opioid pain, treatment and device markets efforts to find alternatives and effective replacements for opioids.
Active biotech and pharma companies in the markets this week include: Q BioMed Inc. (otcqb:QBIO), Collegium Pharmaceutical, Inc.
Q BioMed Inc. (otcqb:QBIO) BREAKING NEWS: Q BioMed Launches Non-Opioid Treatment for Metastatic Bone Pain – Q BioMed a commercial stage biotech company, announced today the launch of its FDA approved non-opioid drug Strontium89 (Strontium Chloride Sr-89 Injection, USP), which has been shown in clinical studies to help relieve persistent pain associated with cancer that has metastasized to bone.
In several multicenter, placebo-controlled trials in cancer patients with persistent pain after external beam radiation therapy for bone metastases, pain relief occurred in more patients treated with a single injection of Strontium89 than in patients treated with an injection of placebo, with a greater percentage of patients experiencing pain scores of zero without any need for opioid or non-opioid rescue analgesics.
Due to the opioid crisis, clinicians and patients are looking for pain management alternatives.
Strontium89, which is administered every 3 months, has been shown to relieve pain in over 70% of patients who received the treatment.
We look forward to being able to help serve the unmet needs of the millions of patients suffering from debilitating bone pain associated with metastatic cancer.
Years of well-documented data show that Strontium89 can help alleviate the pain suffered by most patients with painful bone metastases.
We believe this drug has a very important role to play as clinicians move toward proven non-opioid therapeutics for pain palliation,” stated Q BioMed CEO Denis Corin.
COLL, -0. 62%, a specialty pharmaceutical company committed to being the leader in responsible pain management, recently announced that it has entered into a definitive agreement to acquire the U. S. rights to the Nucynta Franchise from Assertio Therapeutics, Inc. (“Assertio”) for $375. 0 million in cash.
Mallinckrodt plc MNK, -7. 50% a global biopharmaceutical company, recently confirmed enrollment of the first patient in the company’s Phase 4, multi-center, multiple-dose, open-label study to assess the effects of Acthar Gel as a therapy option in patients with severe keratitis.
“I am pleased that the first patient has been enrolled in this important Phase 4 study, the results of which may potentially provide data to further support Acthar Gel as a treatment option in appropriate keratitis patients. “
Teva Pharmaceutical Industries Limited TEVA, -6. 54% recently announced positive results from two Phase 2/3 trials evaluating AJOVY(R) (fremanezumab) in patients in Japan.
|drug||DRUGBANK||Strontium chloride Sr-89|
- BioXcel Therapeutics Announces FDA Clearance of IND Application for BXCL501 for the Treatment of Opioid Withdrawal Symptoms
- Syntrix Discovers Desmetramadol is G-Protein Biased Opioid Receptor Agonist